Chrome Extension
WeChat Mini Program
Use on ChatGLM

Efficacy and Clinicogenomic Correlates of Response to Immune Checkpoint Inhibitors Alone or with Chemotherapy in Non-Small Cell Lung Cancer

Nature communications(2023)SCI 1区

Univ Texas MD Anderson Canc Ctr | Department of Imaging Physics | Division of Hematology and Oncology | Department of Biostatistics | Department of Radiology | Department of Radiation Oncology | Department of Thoracic Imaging | Department of Pathology | Department of Medicine

Cited 17|Views89
Abstract
The role of combination chemotherapy with immune checkpoint inhibitors (ICI) (ICI-chemo) over ICI monotherapy (ICI-mono) in non-small cell lung cancer (NSCLC) remains underexplored. In this retrospective study of 1133 NSCLC patients, treatment with ICI-mono vs ICI-chemo associate with higher rates of early progression, but similar long-term progression-free and overall survival. Sequential vs concurrent ICI and chemotherapy have similar long-term survival, suggesting no synergism from combination therapy. Integrative modeling identified PD-L1, disease burden (Stage IVb; liver metastases), and STK11 and JAK2 alterations as features associate with a higher likelihood of early progression on ICI-mono. CDKN2A alterations associate with worse long-term outcomes in ICI-chemo patients. These results are validated in independent external ( n = 89) and internal ( n = 393) cohorts. This real-world study suggests that ICI-chemo may protect against early progression but does not influence overall survival, and nominates features that identify those patients at risk for early progression who may maximally benefit from ICI-chemo.
More
Translated text
Key words
Cancer immunotherapy,Chemotherapy,Non-small-cell lung cancer,Science,Humanities and Social Sciences,multidisciplinary
PDF
Bibtex
AI Read Science
AI Summary
AI Summary is the key point extracted automatically understanding the full text of the paper, including the background, methods, results, conclusions, icons and other key content, so that you can get the outline of the paper at a glance.
Example
Background
Key content
Introduction
Methods
Results
Related work
Fund
Key content
  • Pretraining has recently greatly promoted the development of natural language processing (NLP)
  • We show that M6 outperforms the baselines in multimodal downstream tasks, and the large M6 with 10 parameters can reach a better performance
  • We propose a method called M6 that is able to process information of multiple modalities and perform both single-modal and cross-modal understanding and generation
  • The model is scaled to large model with 10 billion parameters with sophisticated deployment, and the 10 -parameter M6-large is the largest pretrained model in Chinese
  • Experimental results show that our proposed M6 outperforms the baseline in a number of downstream tasks concerning both single modality and multiple modalities We will continue the pretraining of extremely large models by increasing data to explore the limit of its performance
Try using models to generate summary,it takes about 60s
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Related Papers

Pre-treatment with Systemic Agents for Advanced NSCLC Elicits Changes in the Phenotype of Autologous T Cell Therapy Products

Charlotte O. ' Brien Gore, Amy Billman, Suchete Hunjan, Jayne Colebrook,Desmond Choy, Wilson Li, Jack Haynes,Jennifer Wade, Emily Hobern,Louisa Mcdonald,Sophie Papa,Martijn Brugman,
MOLECULAR THERAPY ONCOLYTICS 2023

被引用1

Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn
Chat Paper

要点】:该研究探讨了非小细胞肺癌(NSCLC)患者使用免疫检查点抑制剂(ICI)单独或联合化疗的治疗效果及临床基因组学相关性,发现单独使用ICI与联合化疗相比,虽然早期进展率较高,但长期生存率相似,并确定了与早期进展和长期生存相关的特定基因特征。

方法】:研究采用回顾性分析,对1133名NSCLC患者的治疗数据进行了统计和综合建模分析。

实验】:研究验证了PD-L1、疾病负担(如肝转移)、STK11和JAK2基因变异与早期进展的相关性,以及CDKN2A基因变异与长期预后不良的相关性,结果在独立的外部队列(n=89)和内部队列(n=393)中得到了验证。